How does atorvastatin’s HMG‑CoA reductase inhibition potency compare with Lipitor’s?
“Lipitor” is the brand name for atorvastatin. So there is not a separate, distinct “potency” for Lipitor versus atorvastatin. Lipitor contains atorvastatin as the active ingredient, and its cholesterol-lowering effect comes from atorvastatin’s inhibition of HMG‑CoA reductase.
Is “Lipitor potency” different at different doses (10/20/40/80 mg)?
Dose differences change exposure (how much active drug is taken), which affects the degree of HMG‑CoA reductase inhibition in the body and the size of the LDL‑C reduction, but the mechanism is the same because the drug is the same (atorvastatin).
Are there differences between brands or generic atorvastatin?
Different manufacturers of atorvastatin generics or brands should deliver the same active drug (atorvastatin). Differences that can affect real-world response usually come from formulation/excipients or patient-specific factors (absorption, adherence), not from different HMG‑CoA reductase inhibition potency of the active ingredient.
What you can look for if you mean “potency” in a lab sense
If you’re comparing “potency” as in an in vitro measure (like an IC50 for HMG‑CoA reductase inhibition), that would be about the active molecule’s pharmacology, not the trade name. In practice, atorvastatin’s lab potency doesn’t change just because it’s sold as Lipitor.
If you share whether you mean “potency” as (1) in vitro enzyme inhibition (IC50), (2) clinical LDL‑C reduction at specific doses, or (3) strength in terms of mg-for-mg, I can tailor the comparison to that specific definition.